The Italian Medicines Agency (AIFA) has granted approval to conduct human clinical trials on raloxifene, a generic osteoporosis drug to treat paucisymptomatic Covid-19 patients.
Long-term treatment with selective estrogen receptor modulators improves muscle, respiratory, and skeletal function without weakening bone in new mouse studies…